HLA class II transgenic mice develop a safe and long lasting immune response against StreptInCor, an anti-group A streptococcus vaccine candidate

Imagem de Miniatura
Arquivos
art_GUERINO_HLA_class_II_transgenic_mice_develop_a_safe_2011.PDF (1.03 MB)
Citações na Scopus
29
Tipo de produção
article
Data de publicação
2011
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCI LTD
Autores
Citação
VACCINE, v.29, n.46, p.8250-8256, 2011
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Streptococcus pyogenes infections remain a health problem in several countries because of post-streptococcal sequelae, such as rheumatic fever and rheumatic heart disease. We developed a vaccine epitope (StreptInCor) composed of 55 amino acid residues of the C-terminal portion of the M protein that encompasses both T and B cell protective epitopes. Recently, by using human blood samples, we showed that the StreptInCor epitope is able to bind to different HLA class 11 molecules and that it could be considered a universal vaccine epitope. In the present work, we evaluated the immune response of HLA class II transgenic mice against aluminum hydroxide-absorbed StreptInCor. After a period of one year, several organs were analyzed histologically to verify the safety of the candidate vaccine epitope. Our results showed that StreptInCor is able to induce robust and safe and long lasting immune response without deleterious reactions in several organs. In conclusion, the results presented here indicate that StreptInCor could be considered a safe vaccine against severe streptococcus-induced diseases.
Palavras-chave
S. pyogenes, Vaccine, HLA class II transgenic mice, Humoral immune response, Histopathology
URI
https://observatorio.fm.usp.br/handle/OPI/22602
Referências
  1. Alpert NR, 2002, AM J PHYSIOL-HEART C, V283, pH1446, DOI 10.1152/ajpheart.00274.2002
  2. FISCHETTI VA, 1991, SCI AM, V264, P58
  3. Singh M, 1999, NAT BIOTECHNOL, V17, P1075, DOI 10.1038/15058
  4. LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
  5. Hu MC, 2002, INFECT IMMUN, V70, P2171, DOI 10.1128/IAI.70.4.2171-2177.2002
  6. Foth BJ, 2006, P NATL ACAD SCI USA, V103, P3681, DOI 10.1073/pnas.0506307103
  7. Kotloff KL, 2004, JAMA-J AM MED ASSOC, V292, P709, DOI 10.1001/jama.292.6.709
  8. Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000
  9. Guilherme L, 2011, J BIOL CHEM, V286, P6989, DOI 10.1074/jbc.M110.132118
  10. Carapetis JR, 2005, LANCET INFECT DIS, V5, P685, DOI 10.1016/S1473-3099(05)70267-X
  11. Olive C, 2007, VACCINE, V25, P1789, DOI 10.1016/j.vaccine.2006.11.031
  12. Guilherme L, 2011, ADV CLIN CHEM, V53, P31, DOI 10.1016/S0065-2423(11)53002-1
  13. Guilherme L, 2006, AUTOIMMUNITY, V39, P31, DOI 10.1080/08916930500484674
  14. TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350
  15. Guilherme L, 2004, AM J PATHOL, V165, P1583, DOI 10.1016/S0002-9440(10)63415-3
  16. Fae KC, 2006, J IMMUNOL, V176, P5662
  17. Shulman ST, 2009, CLIN INFECT DIS, V49, P78, DOI 10.1086/599344
  18. Madsen L, 1999, P NATL ACAD SCI USA, V96, P10338, DOI 10.1073/pnas.96.18.10338
  19. Martins TB, 2008, INT IMMUNOL, V20, P445, DOI 10.1093/intimm/dxn004
  20. Chapoval SP, 1998, J IMMUNOL, V161, P2032
  21. Cunningham MW, 2004, MOL IMMUNOL, V40, P1121, DOI 10.1016/j.milimm.2003.11.023
  22. Ellis NMJ, 2005, J IMMUNOL, V175, P5448
  23. Gorton D, 2010, J IMMUNOL METHODS, V355, P80, DOI 10.1016/j.jim.2010.02.013
  24. Bradley DS, 1997, J CLIN INVEST, V100, P2227, DOI 10.1172/JCI119760
  25. CARDIOLOGIA SBD, 2009, ARQ BRAS CARDIOL S4, V93, P3
  26. DALE JB, 1986, J EXP MED, V164, P1785, DOI 10.1084/jem.164.5.1785
  27. Galvin JE, 2002, AM J PATHOL, V160, P297, DOI 10.1016/S0002-9440(10)64373-8
  28. GonzalezGay MA, 1996, HUM IMMUNOL, V50, P54, DOI 10.1016/0198-8859(96)00123-1
  29. GOODSON HV, 1993, P NATL ACAD SCI USA, V90, P659, DOI 10.1073/pnas.90.2.659
  30. Gorton D, 2009, INFECT IMMUN, V77, P2177, DOI 10.1128/IAI.01514-08
  31. Guilherme L, 2006, CLIN DEV IMMUNOL, V13, P125, DOI 10.1080/17402520600877026
  32. Guilherme L, 2007, CURR PROTEIN PEPT SC, V8, P39, DOI 10.2174/138920307779941488
  33. JONES KF, 1986, J EXP MED, V164, P1226, DOI 10.1084/jem.164.4.1226
  34. KAPLAN MH, 1963, AM HEART J, V65, P426, DOI 10.1016/0002-8703(63)90020-6
  35. Kotloff KL, 2004, PEDIATR INFECT DIS J, V23, P765, DOI 10.1097/01.inf.0000136296.98686.c5
  36. KRAUS W, 1989, INFECT IMMUN, V57, P2457
  37. KRAUS W, 1989, J EXP MED, V169, P481, DOI 10.1084/jem.169.2.481
  38. Lymbury RS, 2003, J AUTOIMMUN, V20, P211, DOI 10.1016/S0896-8411(03)00026-X
  39. Nabozny GH, 1996, J EXP MED, V183, P27, DOI 10.1084/jem.183.1.27
  40. Pan SC, 1998, J IMMUNOL, V161, P2925
  41. Ribeiro SP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011072
  42. SARGENT SJ, 1987, J IMMUNOL, V139, P1285

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/19